John D. Mendlein
2015
In 2015, John D. Mendlein earned a total compensation of $3.9M as Chief Executive Officer and Director at aTYR PHARMA, a 181% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $210,374 |
|---|---|
| Option Awards | $3,231,371 |
| Salary | $472,750 |
| Other | $14,076 |
| Total | $3,928,571 |
Mendlein received $3.2M in option awards, accounting for 82% of the total pay in 2015.
Mendlein also received $210.4K in non-equity incentive plan, $472.8K in salary and $14.1K in other compensation.
Rankings
In 2015, John D. Mendlein's compensation ranked 2,236th out of 13,638 executives tracked by ExecPay. In other words, Mendlein earned more than 83.6% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 2,236 out of 13,638 | 84th |
Division Manufacturing | 803 out of 5,190 | 85th |
Major group Chemicals And Allied Products | 286 out of 1,854 | 85th |
Industry group Drugs | 225 out of 1,528 | 85th |
Industry Biological Products, Except Diagnostic Substances | 40 out of 254 | 84th |
Source: SEC filing on March 30, 2017.
Mendlein's colleagues
We found three more compensation records of executives who worked with John D. Mendlein at aTYR PHARMA in 2015.